These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32155012)

  • 1. Evaluation of growth hormone co-treatment in in vitro fertilization in patients responding better to the GnRH antagonist short protocol.
    Macedo JF; Oliveira MR; Gomes LMO; Macedo GC; Macedo GC; Gomes DO; Martins OG; Ambrogi BO; Santos SISD
    JBRA Assist Reprod; 2020 May; 24(2):147-151. PubMed ID: 32155012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of clinical outcomes between the depot gonadotrophin-releasing hormone agonist protocol and gonadotrophin-releasing hormone antagonist protocol in normal ovarian responders.
    Xia M; Zheng J
    BMC Pregnancy Childbirth; 2021 May; 21(1):372. PubMed ID: 33975553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cumulative live birth rates per oocytes retrieved cycle: evaluation of clinical outcomes of IVF/ICSI].
    Wu CX; Zhang T; Shu L; Huang J; Diao FY; Ding W; Gao Y; Wang W; Mao YD; Cui YG; Liu JY
    Zhonghua Fu Chan Ke Za Zhi; 2018 Mar; 53(3):160-166. PubMed ID: 29609229
    [No Abstract]   [Full Text] [Related]  

  • 5. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
    Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Gonadotropin-releasing hormone antagonist protocol in patients with risk of poor response to ovarian stimulation in IVF-ET].
    Sun Y; Zhu YM
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 May; 38(3):305-10. PubMed ID: 19504641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GnRH antagonist rescue in high responders at risk for OHSS results in excellent assisted reproduction outcomes.
    Hill MJ; Chason RJ; Payson MD; Segars JH; Csokmay JM
    Reprod Biomed Online; 2012 Sep; 25(3):284-91. PubMed ID: 22796230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
    Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of growth hormone supplementation with ultrashort GnRH antagonist in IVF/ICSI for poor responders; randomized controlled trial.
    Mohammad EH; Abou El Serour AG; Mohamed EAH; Abbasy AH; Zaatar M; Rageh KA; Shafeek MM; Issak ER
    Taiwan J Obstet Gynecol; 2021 Jan; 60(1):51-55. PubMed ID: 33495008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stop GnRH-Agonist Combined With Multiple-Dose GnRH-Antagonist Protocol for Patients With "Genuine" Poor Response Undergoing Controlled Ovarian Hyperstimulation for IVF.
    Orvieto R; Kirshenbaum M; Galiano V; Elkan-Miller T; Zilberberg E; Haas J; Nahum R
    Front Endocrinol (Lausanne); 2020; 11():182. PubMed ID: 32528403
    [No Abstract]   [Full Text] [Related]  

  • 14. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation].
    Kdous M; Chaker A; Bouyahia M; Zhioua F; Zhioua A
    Tunis Med; 2009 Dec; 87(12):834-42. PubMed ID: 20209851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
    Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
    Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
    Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
    Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of cetrorelix versus ganirelix in gonadotropin-releasing hormone antagonist cycles for preventing premature luteinizing hormone surges and on clinical outcomes of IVF-ET cycles].
    Zhang J; Zhou X; Chen Y; Zhang Q; Li Y; Zhe J; Chen X; Chen S
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Oct; 39(10):1207-1212. PubMed ID: 31801718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraindividual Embryo Morphokinetics Are Not Affected by a Switch of the Ovarian Stimulation Protocol Between GnRH Agonist vs. Antagonist Regimens in Consecutive Cycles.
    Dietrich JE; Freis A; Beedgen F; von Horn K; Holschbach V; Liebscher J; Strowitzki T; Germeyer A
    Front Endocrinol (Lausanne); 2020; 11():246. PubMed ID: 32411093
    [No Abstract]   [Full Text] [Related]  

  • 20. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization.
    Berin I; Stein DE; Keltz MD
    Fertil Steril; 2010 Feb; 93(2):360-3. PubMed ID: 19131055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.